Earnings Feed
Start Free
REGENXBIO Inc.·4

Jul 1, 8:08 PM ET

PAKOLA STEVE 4

Research Summary

AI-generated summary

Updated

REGENXBIO (RGNX) CMO Steve Pakola Exercises Options, Sells 56,333 Shares

What Happened Steve Pakola, Chief Medical Officer of REGENXBIO (RGNX), exercised options to acquire 36,725 shares on 2026-07-01 at $7.86 per share (cost $288,659) and immediately sold those 36,725 shares in an open-market transaction at $12.86 each (proceeds $472,284). Earlier, on 2026-06-29 he sold 19,608 shares in the open market at a weighted-average price of $11.04 (proceeds $216,472). Combined, Pakola sold 56,333 shares for total gross proceeds of $688,756. The filing also shows a $0.00 disposition entry for the derivative (the option), reflecting conversion/exercise of the option.

Key Details

  • Transaction dates and prices:
    • 2026-06-29: Sold 19,608 shares @ weighted avg $11.04 = $216,472 (executed in multiple trades at $11.00–$11.18).
    • 2026-07-01: Exercised options to acquire 36,725 shares @ $7.86 = $288,659 (Form 4 “M” acquisition).
    • 2026-07-01: Sold 36,725 shares @ $12.86 = $472,284.
    • 2026-07-01: Derivative disposition reported at $0.00 (reflects option extinguished on exercise).
  • Total sold: 56,333 shares for $688,756 in gross proceeds; total cash paid to exercise: $288,659.
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Notable footnotes:
    • Filing notes at least one sale was effected pursuant to a Rule 10b5‑1 trading plan.
    • The 6/29 sale was executed in multiple trades (prices ranged $11.00–$11.18; reported price is weighted average).
    • The option grant (right to buy 103,698 shares) vested 25% on Jan 2, 2026 and the balance vests monthly over the next 36 months while employed.
  • Filing date: Form 4 filed July 1, 2026 — appears timely based on reported transaction dates.

Context

  • This was an option exercise followed by an immediate sale (a common “cashless” or same‑day sell-to-cover pattern): Pakola paid the exercise price to convert options into shares and then sold those shares in the market on the same day. The $0.00 derivative disposition entry simply records that the option right was extinguished upon exercise.
  • Sales by executives can be routine (liquidity, tax withholding, or plan-driven). Purchases tend to be stronger signals of bullish conviction; this filing is primarily sales. No speculation on motivation is offered — just the reported facts.